Peps
What is Tirzepatide?
Tirzepatide is a dual-incretin medicine with distinct product and indication contexts. Its clinical-trial material is not interchangeable with a research-use vial.
Biological role or research focus
Incretin-related glucose and appetite regulation.
Mounjaro, Zepbound, compounded preparations, and research products have distinct identities.
Role reference: MedlinePlus: Tirzepatide injection ↗
Names you may encounter
Mounjaro · Zepbound
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- GIP / GLP-1 receptor agonist
- Main research area
- Diabetes, weight, and related indications
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Molecular structure
Mechanism & research rationale
It activates GIP and GLP-1 receptor pathways. Effects on glucose regulation, stomach emptying, and appetite are evaluated through indication-specific clinical trials.
Clinical uses & product context
The medication reference covers selected diabetes and weight-management populations and obstructive sleep apnea in adults with obesity. The exact product label defines eligibility and use.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2022
SURMOUNT-1
Tirzepatide Once Weekly for the Treatment of Obesity.
- Population / model
- 2,539 adults with obesity, or overweight and a weight-related complication, without diabetes.
- Study design
- Seventy-two-week blinded placebo-controlled study with gradual escalation.
- Main finding
- Mean weight reductions were 15.0%, 19.5%, and 20.9% across active groups versus 3.1% with placebo. Gastrointestinal effects were common.
- Limits & context
- This trial cannot be compared directly with STEP 1 as if participants were randomized between the two drugs. Outcomes depend on population, duration, regimen, and handling of discontinuation.
Source: Tirzepatide Once Weekly for the Treatment of Obesity. ↗
Human randomized trial · 2021
SURPASS-2 direct comparison in type 2 diabetes
How did the studied tirzepatide regimens compare with semaglutide in this diabetes trial?
- Population / model
- 1,879 patients with type 2 diabetes; mean baseline HbA1c 8.28%.
- Study design
- Open-label randomized phase 3 trial lasting 40 weeks. Three tirzepatide groups were compared with semaglutide 1 mg weekly.
- Main finding
- Mean HbA1c fell by 2.01–2.30 percentage points in the tirzepatide groups and 1.86 with semaglutide. Weight reductions were greater with tirzepatide; between-group differences ranged from 1.9 to 5.5 kg. Gastrointestinal adverse effects were common.
- How to read it
- This is a direct comparison, but only for its actual regimens, population, and outcomes. HbA1c percentage points and percentage weight change are different measures.
- Limits & context
- Open-label design; the semaglutide comparator was 1 mg, not the 2.4 mg obesity regimen. It is not a universal ranking across all products or doses. Funded by Eli Lilly.
Human randomized withdrawal trial · 2024
SURMOUNT-4 · continuation versus withdrawal
Was initial weight reduction maintained after switching to placebo?
- Population / model
- 670 adults with overweight or obesity without diabetes who completed a 36-week open-label lead-in; 783 initially enrolled.
- Study design
- Randomized double-blind comparison of continued tirzepatide with placebo for another 52 weeks, alongside diet and activity.
- Main finding
- After a mean 20.9% reduction during lead-in, weight changed by −5.5% with continued treatment versus +14.0% with placebo from week 36 to week 88. At least 80% of the lead-in loss was maintained by 89.5% versus 16.6%.
- How to read it
- The randomized-period change and the total change from enrollment use different baselines. They should not be conflated.
- Limits & context
- Only lead-in completers were randomized. Gastrointestinal events were more common with continued treatment. This does not determine an individual stopping plan or prove that every patient will regain the same amount.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Key precautions
Gastrointestinal reactions, dehydration, pancreatic and gallbladder concerns, and thyroid-tumor warnings matter. Pregnancy planning, oral contraception, and other diabetes medicines require specific clinical review.
Source: MedlinePlus: Tirzepatide injection ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
Comparing metabolic peptides in conversation
The speakers compare personal experiences and describe differences among semaglutide, tirzepatide, and retatrutide. Their tolerability anecdotes are not a head-to-head clinical trial.
Does a comparative trial support the claimed difference in effectiveness or adverse effects?
Caption excerpt reviewed · Claims not independently verified · 2026-10-04
Original episode: RETATRUTIDE: EVERYTHING YOU NEED TO KNOW | Wes Christensen | Fouad Abiad's Real Bodybuilding Podcast
Watch the source discussions
210 matching video records · 4 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Dr. Jones, DC
Doctor Explains Tirzepatide’s Other Benefits Beyond Weight Loss (not what you think) ↗
Captions indexed · Automatic matches need review
Fouad Abiad Media
RETATRUTIDE: EVERYTHING YOU NEED TO KNOW | Wes Christensen | Fouad Abiad's Real Bodybuilding Podcast ↗
Captions indexed · Automatic matches need review
Mind Pump Show
Hormones, Peptides & Body Transformation with Phil Vella CEO of Vita Bella Health | Mind Pump 2882 ↗
Captions indexed · Automatic matches need review
Dr. Trevor Bachmeyer
BPC-157: The Forever Peptide I Take Every Single Day - Dr Trevor Bachmeyer ↗
Captions indexed · Automatic matches need review
Biohackingturkey
Mounjaro Nedir? Zayıflama İlacı Hakkında Bilmeniz Gerekenler ↗
Title match · Captions not indexed
Biohackingturkey
Retatrutide vs Tirzepatide: Hangisi Daha Etkili? ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Which exact product is being discussed?
- Is a podcast describing a study, an approved indication, or a personal experience?
- Mounjaro, Zepbound, compounded preparations, and research products have distinct identities.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Are Mounjaro and Zepbound the same indication?
No. They contain the same molecule but have distinct product-label contexts.
Does SURMOUNT-1 validate every seller’s tirzepatide?
No. A study of a controlled pharmaceutical preparation cannot establish another product’s identity, potency, or clinical safety.
Source: Tirzepatide Once Weekly for the Treatment of Obesity. ↗
What does the additional research establish?
This is a direct comparison, but only for its actual regimens, population, and outcomes. HbA1c percentage points and percentage weight change are different measures. Open-label design; the semaglutide comparator was 1 mg, not the 2.4 mg obesity regimen. It is not a universal ranking across all products or doses. Funded by Eli Lilly.
References & editorial record
- FDA · Unapproved GLP-1 products ↗
- MedlinePlus: Tirzepatide injection ↗
- Tirzepatide Once Weekly for the Treatment of Obesity. ↗
- Frias et al. · NEJM · SURPASS-2 · 2021 ↗
- Aronne et al. · JAMA · SURMOUNT-4 · 2024 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Semaglutide, tirzepatide, retatrutide: why trial context changes the comparison
Understand direct comparisons, diabetes versus obesity populations, and the difference between glucose, weight, and cardiovascular outcomes.
Read the guide →